• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Industrials·6521.T
Share

OXIDE Corporation Stocks

¥ 4180Last Updated 14.07.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

¥ 308.66M

¥ 4180
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

OXIDE Corporation, together with its subsidiaries, develops, manufactures, and sells optical-related products in Japan, the United States, China, and internationally. The company operates through three segments: New Field Business; Semiconductor Business; and Healthcare Business. It offers crystals for scintillation, laser and phosphor, and polarization control, as well as nonlinear optical crystals and others; nonlinear optical devices and crystals; assembled modules and accessories for support devices; CW lasers/pulsed lasers and converters; components; and optical measuring instruments. The company also provides materials and related products for power semiconductors. OXIDE Corporation was incorporated in 2000 and is headquartered in Hokuto, Japan.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very unfavourable
1/7

The average target price of 6521.T is 1450 and suggests 66.3% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 02:16

"The Prisoner's Dilemma": JPMorgan Warns of a Threat to Coinbase and Circle's Profits

15.07.2026 01:24

Inflation data pushed the indices higher. Software developers are under pressure again

15.07.2026 00:57

Biogen shares fell after disappointing data on its Alzheimer's drug

14.07.2026 23:31

Software developers' stocks plummeted following IBM's warning. What's wrong with the sector?

14.07.2026 23:07

Goldman Sachs set a new record for equity trading revenue. Its stock price soared

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026